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CNVArray comparative genomic hybridisation (aCGH) proﬁling is currently the gold standard for genetic diagno-
sis of copy number. Next generation sequencing technologies provide an alternative and adaptable method of
detecting copy number by comparing the number of sequence reads in non-overlapping windows between
patient and control samples.
Detection of copy number using the BlueGnome 8 × 60k oligonucleotide aCGH platform was compared with
low resolution next generation sequencing using the Illumina GAIIx on 39 patients with developmental delay
and/or learning difﬁculties who were referred to the Leeds Clinical Cytogenetics Laboratory. Sensitivity and
workﬂow of the two platforms were compared.
Customised copy number algorithms assessed sequence counts and detected changes in copy number. Imbal-
ances detected on both platforms were compared.
Of the thirty-nine patients analysed, all eleven imbalances detected by array CGH and conﬁrmed by FISH or
Q-PCR were also detected by CNV-seq. In addition, CNV-seq reported one purported pathogenic copy number
variant that was not detected by array CGH.
Non-pathogenic, unconﬁrmed copy number calls were detected by both platforms; however few were con-
cordant between the two.
CNV-seq offers an alternative to array CGH for copy number analysis with resolution and future costs compa-
rable to conventional array CGH platforms and with less stringent sample requirements.
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a. Losses and gains across the genome in a subset of 11 samples from the study (the
remaining samples could not be included as their corresponding NGS and array data
were analysed on different genome builds however all abnormalities are described in
genome build 19). NGS calls were based on regions of three adjacent windows and
compared to the microarray probe that mapped the middle of the three windows. Mi-
croarray calls were made on the basis of three deviating consecutive probes. More ‘sets’
of microarray probes were called as lost or gained than CNV-seq window ‘sets’, which
suggests that the detection of copy number is more optimal using NGS read counts
than ﬂuorescence intensities. Commercial microarray software applies quality scores
to each probe, and therefore most of these probes are not actually called. b. Direct com-
parison of one sample with noisy array data against NGS data showed signiﬁcantly
higher number of array calls compared to any other array case examined (this outlier
was not included in a).
NGS loss NGS normal NGS gain
a
Microarray loss 302 1128 0
Microarray normal 194 553,400 85
Microarray gain 0 1250 10
b
Microarray loss 0 1204 0
Microarray normal 9 48,231 9
Microarray gain 0 1125 11. Introduction
Constitutional chromosomal abnormalities are a frequent cause of
congenital structural malformation and developmental delay
disorders in children [1]. Standard investigation involves karyotyping
G-banded metaphase cells with conﬁrmation of detected
rearrangements using FISH, MLPA or other molecular based tech-
niques [2]. Targeted molecular testing may be an option if the pheno-
type is well described, but limited coverage of genome-wide targets
with low-throughput capability means that this cytogenetic approach
has largely been replaced in the postnatal setting by high-resolution
whole genome DNA array CGH (aCGH) analysis [3,4]. With selectable
resolution according to microarray design, this technology has
heralded a new era of genomics and assisted in the identiﬁcation of
multiple novel microdeletion syndromes [4,5]. It has become the
gold standard for constitutional genetic diagnosis of copy number
variation (CNV). As aCGH has developed from a research to a routine
application, issues with the reproducibility and standardisation of mi-
croarray experiments have been raised [6].
The ultimate resolution for genomic interrogation is at the level of the
base pair. Advances in DNA sequencing technology mean that detection
of copy number variation by sequencing (CNV-seq) is now a realistic op-
tion for whole genome copy number analysis. Initially described in the
analysis of cancer genomes [7,8], high-resolutionmapping of copy num-
ber variation requires alignment of sequenced reads to a reference ge-
nome [9]. Distribution of the aligned reads is then analysed on a
segmental or genomic window-by-window basis to determine differ-
ences in read-depth between the test and reference genomes. An in-
crease in sample read-depth across a window, when compared to the
control sample, represents a gain in genomic material; a reduction in
read-depth suggests a loss [8]. Initial work was based on a high number
of reads with deep coverage across the genome [8–12], a level not com-
patible with the high throughput, cost-sensitive requirements of diag-
nostic service.
We have previously described a method of sample multiplexing to
determine dosage changes in tumour DNA [13]. In addition, we have
compared the copy number proﬁle generated by next generation se-
quencing (NGS) with that obtained by aCGH in DNA from cell lines and
demonstrated that these appear to be almost identical [13]. In this
study we expand this observation to clinical samples by comparing the
results of CNV-seq analysis with the widely used UK gold standard
8 × 60k oligonucleotidemicroarray (oligoarray) for copy number detec-
tion in 39 phenotypically abnormal children. Firstly, we analysed the raw
data of both techniques, without removing poor quality oligonucleotide
probe data prior to microarray analysis. This was performed to compare
the technologies directly, including their ability to detect imbalances
above the noise produced from the technique. Secondly, we use aCNV-seq analysis method that closely resembles the method of analysis
of the microarray to compare the platforms in a diagnostic setting.2. Results
Table 1a and b shows a cross-tabulation of CNV calls at the window
level. For the generation of this table, each microarray probe was com-
pared to the NGSwindow towhich itmaps. NGS calls were based on re-
gions of three adjacent windows, with applied thresholds constructed
from posterior probabilities of ±0.5. These were compared to the mi-
croarray probe that mapped themiddle of the three windows. Microar-
ray calls were made on the basis of three consecutive probes deviating
from the commonly used microarray thresholds of ±0.3. In some
cases NGSwindowswere countedmore than once in these tables, as oc-
casionally a number of consecutive microarray probes map the same
window in the targeted regions of the oligoarray. Comparison of the
two platforms based on individual windows showed that the oligoarray
produce the most calls. The read-depth across the genome was plotted
and compared to the microarray probe location. These plots were then
compared to the distribution of pathogenic genes (genes deﬁned as
morbid in Online Mendelian Inheritance in Man, OMIM). Fig. 1 shows
distributions across chromosome 1. It is clear that the NGS reads are
Fig. 1. The distribution of the reads across chromosome 1 (top track) in comparison to the distribution of the microarray probes on the 8 × 60k (bottom track). Pathogenic genes
(morbid OMIM genes) are shown on the middle track. It is clear that the microarray probes are located to mirror regions of pathogenicity. CNV-seq reads are more evenly spaced
across the genome.
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on the bottom track more closely mirror the Online Mendelian Inheri-
tance in Man genes on the middle track.
Twelve of the thirty-nine samples analysed with the CNV-seq
method were found to contain clinically signiﬁcant copy number var-
iants. These ranged in size from 49 kb to 7.8 Mb. Imbalances of differ-
ent orders were detected (deletions, duplications and triplications)
and some cases had more than one imbalance (Table 2). A full table
of results found in this study is included in the Supplementary mate-
rial, including breakpoints and follow-up analysis. All purported
pathogenic abnormalities were detected across both platforms, with
the exception of a 49 kb deletion at 2q23.1 (sample 10), which was
only detected by the CNV-seq method. This region did not contain
any microarray probes (Fig. 3). The deleted NGS windows within
that region are shown in a background of their neighbouring win-
dows (Fig. 3b). All copy number variants containing morbid OMIM
genes were conﬁrmed using FISH or Q-PCR in cases where suitable
material was available. The 7q11.23 abnormality was detected as a
duplication on the microarray (log2 0.71), but was identiﬁed as a trip-
lication using NGS (log2 1.0402) and FISH (Case 3).
A complete list of the copy number variants called based on the ap-
plied thresholds is included in the Supplementary Table. Different copy
number calls (assumed non-pathogenic) were made on each platform,
which may be due to different controls used on each platform. Each of
these calls was carefully interrogated against the Database of Genomic
Variants [14] to examine the content of the affected region. Most re-
gions were found to contain previously reported non-pathogenic copy
number variation and therefore were not followed up. The regions
containing OMIM genes that could link to the patient's overall clinical
presentation were followed up using FISH or Q-PCR. Of the abnormali-
ties followed up, 6 false positives were detected on oligoarray and 3Table 2
A range of abnormalities of different sizes in different locations in the genome were detecte
platforms and were validated by FISH, with the exception of a (49 kb) deletion of chromos
Sample Chromosome Position
Start End
1 16 29591395 30172134
2 21 43269253 48062257
15 98278672 102370904
3 7 72703446 74129963
4 14 68872493 75759128
7 16 1 2569135
3318842 4678939
4938802 5199796
10 2 148792468 148842172
16 3 62301648 69944162
19 3 138133378 145939687
21 16 4312849 4693138
16 4946452 5237437
25 15 30545167 32419660
8 9466830 9709038
27 17 7065530 7673270
28 1 145118135 145728993were detected using CNV-seq. Comparison of the calls generated by
the two tests showed little concordance.
The number of aligned reads obtained per sample ranged between 2
and 7 million reads (median 3.4 million reads) which produced resolu-
tions between 37 and 130 kb (median 76 kb). Read numbers differed
due to improving numbers of reads obtained from the sequencer with
successive runs and pipetting error when pooling samples.
3. Discussion
3.1. Comparison of raw data; assessment of capability of the technology
Direct comparison of the rawdata generated from the two platforms
(analysis method #1) showed that the microarray platform results in
more spurious calls (Table 1a, b). Since analysis of the same sample
using the proprietary oligoarray software produced signiﬁcantly fewer
calls it was assumed that these were discounted due to low quality
(i.e., spots which do not ﬁt the model of data are removed from further
analysis). These are likely to be non-biological hybridisation signals that
occur during an array experiment due to technical noise. The commer-
cial software uses a quality score system that assesses the quality of
each spot in relation to its location on the chip and discards those that
fall outside the thresholds of a normal distribution. This preliminary
analysis highlights the fact that analogue techniques inherently pro-
duce more noise.
In the direct comparisons between the raw NGS and oligoarray data,
one sample (Table 1b) produced signiﬁcantlymore calls compared to the
average array case. This sample had initially failed on the proprietary
oligoarray platform due to the high level of noise. These ﬁndings provide
evidence thatwith quality control not applied, particularly in a sample of
poor quality, there aremore callswhen comparing oligoarray to CNV-seqd across both platforms. All purported pathogenic abnormalities were detected on both
ome 2, which was conﬁrmed by Q-PCR.
Chromosome band Genomic length Gain/loss
16p11.2 580,739 Loss
21q22.3 4,793,004 Loss
15q26.3 4,092,232 Gain
7q11.23 1,426,517 Triplication
14q24 6,886,635 Gain
16p13.3 2,569,134 Gain
16p13.3 1,360,097 Gain
16p13.3 260,994 Gain
2q23.1 49,704 Loss
3p14.1 7,642,514 Loss
3q23 7,806,309 Loss
16p13.3 380,289 Gain
16p13.3 290,985 Gain
15q13.3 1,874,493 Loss
8p23.1 242,208 Gain
17p13.1 607,740 Loss
1q21.1 610,858 Loss
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ful result. This analysis also allowed a direct comparison of calls of imbal-
ance on the basis of NGS window and oligoarray probe location.
An attempt was made to analyse the NGS data using thresholds
constructed from posterior probabilities of 0.5. Using this approach, a
large number of calls were generated,making analysis, follow-up and in-
terpretation particularly difﬁcult; therefore it is not recommended to an-
alyse CNV-seq in this way.
Analysis of the rawNGS data showed that the readdistributionﬁtted
well with the gamma model. The approach used for the analysis of the
39 patients in comparison to the oligoarray (analysis method #2)
could not be modelled in this way because windows were segmented
according to similar log2 ratio. As a segmentation technique is applied
in commercial array CGH analysis, it was deemed necessary to base
our NGS approach on this method.
3.2. Quality and volume of DNA
Although 2 μg of DNA was used as starting material, a successful li-
brary preparation (with comparable sequencing quality and data out-
put) was achieved from as little as 150 ng in a single case; as picogram
quantities are loaded onto the sequencer, it is likely that much lower
quantities would be sufﬁcient. We have previously reported copy num-
ber variation detection in tumour samples with starting quantities as
low as 5 ng [13]. CNV-seq was more tolerant of poor quality DNA, with
one abnormality failing on oligoarray and producing a successful result
on CNV-seq, as previously mentioned. Our group has also successfully
carried out copy number analysis on formalin-ﬁxed parafﬁn-embedded
tissue [13], from which isolated DNA is frequently of poor quality. The
low DNA and quality requirements of CNV-seq should reduce the need
for repeat samples, and also provide results where a repeat sample is
not possible.
3.3. Resolution
The detection of an abnormality using CNV-seq that was not
detected using oligoarray demonstrates the power of this technique;
however it is highly likely that the opposite would be true of the very
small imbalances that fall within the targeted regions of the array. The
number of data points across the genome is 60,000 probes using the
oligoarray and 75,000 windows using CNV-seq at this read-depth.
This suggests that more abnormalities would be detected on average
across the genome using CNV-seq compared to oligoarray (only two
windows/probes are required to call an imbalance). Higher resolution
could be achieved by multiplexing fewer samples per lane, and there-
fore obtaining more reads per sample, reducing the genomic region
covered by a 40 test read window.
We found that 8 samples per ﬂow cell lane of the GAIIx yielded suf-
ﬁcient reads to result in resolution comparable to the oligoarray with-
out a substantial increase in cost to the current diagnostic platform of
choice. The average resolution (74 kb) of the CNV-seqwas signiﬁcantly
better than the backbone resolution of an oligoarray, but lower than the
targeted regions of an optimal oligoarray (48 kb). A fair comparison of
the resolution obtained by the two platforms cannot be made since
the NGS reads are scattered uniformly over the genomewhereasmicro-
array probes are concentrated in predeﬁned clinically important re-
gions (Fig. 1). This can often aid in the interpretation of the results
from oligoarray because imbalances are more likely to be detected in
well-studied regions, whereas CNV-seq may detect imbalances in re-
gions of poor annotation. However, with the advent of CNV-seq it is
likely that information in these less well-studied regions will improve.
The oligonucleotide probes are 60 nucleotides in length and the
length of a read in this method of CNV-seq is 74 bp. CNV-seq will
therefore allow detection of imbalances in more repetitive regions
as reads are less likely to map more than one region. Repetitive loci
are not included in the design of an oligoarray in order to preventnoise from hybridisation of a probe to more than one locus and there-
fore imbalances will not be detected in repetitive regions using this
platform. With the higher read count of the HiSeq, mapping could
be improved even further at no extra cost. Most centres use at least
100 bp reads on this platform, with some up to 150 bp and usually
paired end reads are employed, which would further improve map-
ping into repetitive regions. For diagnostic use however, a balance be-
tween the length of time to perform the sequencing, the resolution
and the cost is required.
It must be noted that although the majority of laboratories in the
United Kingdomuse the 8 × 60kmicroarray for this type of testing, out-
side of the UK higher resolution microarray platforms are employed.
Evaluation of CNV-seq in light of the cost and resolution of these plat-
forms is of obvious importance.
3.4. Controls and non-pathogenic CNV discordance
Non-pathogenic CNVs (not conﬁrmed) detected by the two plat-
forms were often different. One plausible explanation for the ob-
served discordance could be that the backbone resolution of the
NGS platform was higher than that of the oligoarray. A larger number
of calls would therefore be expected in regions where the array has
limited detection capability. It could also be argued that the digital
nature of the NGS data would make a false positive less likely to be
generated. In comparison, the quality of the array data can ﬂuctuate
more and vary between experiments.
The difference may also be due to the different controls used in the
two assays. Oligoarray requires a control to be run in each experiment
alongside the test case for practical reasons. CNV-seq on the other hand
produces digital data and therefore a previously sequenced control pre-
pared in the same way, can be utilised, eliminating batch-associated
CNVs and allowing more streamlined analysis from one run to the
next. This also allows the option of multiple controls compared to one
sample. For instance, if an imbalance is called at a borderline log2 ratio
with use of a speciﬁc control, then that test case could be compared to
a different control to conﬁrm the abnormality before any follow-up is
performed. There is also the option of population-speciﬁc controls, in
cases where ethnicity is known.
This study was carried out for autosomal analysis only as a mixed
sex control was used. Ideally, two controls of different sexes made
frommultiple samples of mixed race, preparedwithin the same labora-
tory, using the same sequencer, would be used. This would reduce noise
and decrease the number of those called non-pathogenic copy number
variants from population-speciﬁc groups. It was noted prior to this
study that a high coverage control produced less noise than a control
of the same coverage with the test sample. Our control had approxi-
mately 6× higher coverage than the median test sample (20 million
versus a median of 3.4 million reads); in practice this would mean
that control read variability was less profound making true changes in
the test sample more noticeable.
3.5. Application of CNV-seq in the diagnostic laboratory
The availability of a sequencing platform is likely to be the stumbling
block for the introduction of CNV-seq in diagnostic laboratories. Access
to core sequencing facilities makes sequencing more affordable and ac-
cessible. Illumina also has another platform available, the MiSeq, which
is more affordable for the initial outlay, but sequencing cost is such that
it would not be efﬁcient for this test, and the higher throughput plat-
forms such as the GAIIx or the HiSeq are more cost-effective.
The adaptability of CNV-seq is extremely attractive for a diagnostics
laboratory. Read numbers could be dramatically reduced compared to
those sequenced here, to produce a very low resolution method which
would be more suitable in cases where interpretation of the result
may be a problem, such as in prenatal diagnosis, or the number of
reads could be dramatically increased if a very small imbalance is to be
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sequencing service available to the user; however those with the option
could offer a quick result with short reads, yet improved mappability
with longer reads. Different sequencing tests on the same patient
could also bemerged, so as to improve coverage in certain regions, a fea-
ture which has never before been possible in diagnostic testing. The in-
crease in number of reads will improve breakpoint reﬁnement, which is
an essential focus of the detection of CNVs. This could also aid in the in-
terpretation of an abnormality showing differing phenotypic expression
across family members.
In the future it is likely that CNV-seq could be coupled with other
analyses in a single test as was performed in a recent study by Sarhadi
et al. [15]. Paired-end sequencing, although not cost effective for a diag-
nostic service currently, may be used to detect balanced rearrangements
in addition to copy number; methods for this analysis have already been
developed [16]. Exome sequencing may also be an option, and tools are
available for this type of analysis, enabling SNP calling alongside the
copy number analysis [17,18]. As the cost of exome sequencing falls,
this may become a practical diagnostic option for measuring gene copy
number changes, although unlike CNV-seq, it would not be a genome-
wide survey.
3.6. Illustrative abnormal cases
3.6.1. Case 3 — 7q triplication
This case was particularly interesting, as a chromosome 7 duplica-
tion was reported on the oligoarray but was later found to be a triplica-
tion by interphase FISH using the Vysis ELN FISH probe. CNV-seq also
revealed the presence of four copies of this locus in the patient genome.
The digital nature of the NGS data allows determination of the exact
copy number of each locus in the genome examined. This is certainly
more challenging with the use of analogue data, such as the oligoarray
data. The log2 ratio value of each segment called by NGS accurately fol-
lows the copy number allowing for a precise characterisation of the im-
balance involved, i.e. 2 copies (expected log2, 0.58) and 3 copies
(expected log2, 1). It must be noted however that triplications are
detected by microarray in routine practice; it could be that this was of
poorer quality.
3.6.2. Case 10 — 2q23.1 microdeletion
A 10-year old patient with developmental delay, microcephaly
and a Smith–Magenis request for investigation was initially referred.
Analysis on the oligoarray platform showed no copy number changes
associated with the patient's clinical presentation. CNV-seq revealed a
microdeletion on chromosome band 2q23.1 of approximately 49 kb.
This was the only discrepant result between the two platforms. The
region is poorly covered by oligonucleotide probes on the array chip
(Fig. 3) whereas the CNV-seq method generates read depth informa-
tion across the whole genome at a reasonably similar resolution.
Fig. 3b shows only 3 consecutive windows in the deleted region to
present with lower read counts compared to their neighbouringTable 3
Comparison of CNV-seq with the 8 × 60k oligoarray; main points included.
CNV-seq
Even coverage across the genome
Expected to detect imbalances in poorly annotated regions
Order of multiplexing can be altered to the resolution required for a speciﬁc application
Sequencing data from previous experiments can be utilised as a control
Sequencing data can be obtained from low quality and quantity of genomic DNA
Ability to use paired-end reads for the detection of balanced rearrangements
Eventually, the use of one platform for multiple applications, i.e. detection of copy numb
changes, balanced rearrangements, mutations, UPD etc
At the moment, practically more difﬁcult to be used as a diagnostic test in cytogenetics, a
to the facility and a lot of expertise in data processing are required
Cost of running the service is higher in comparison, but expected to drop in time and wi
use of higher capacity sequencerswindows, demonstrating the power of the algorithm to accurately de-
tect such small changes. Interrogation of the CNV call against the Da-
tabase of Genomic Variants [14] showed a mental retardation
autosomal dominant I (MBD5 gene, OMIM #156200) disease gene
to be contained within the region. Loss of this gene has been de-
scribed in the recently characterised 2q23.1 microdeletion syndrome
[19]. The patient's phenotype ﬁtted well with that described in the lit-
erature. Interestingly, it has been stated that several 2q23.1
microdeletion cases had initially given the clinical impression of
Angelman, Rett or Smith–Magenis syndromes, as was the case for
our patient [20]. Follow-up Q-PCR studies conﬁrmed the 2q23.1 dele-
tion and when received, Q-PCR analysis of parental samples will be
performed to determine the inheritance of this ﬁnding.
3.6.3. Case 7 — child with Rubinstein–Taybi syndrome
3.6.3.1. Case 21 — parental analysis. A child with developmental delay
was referred for cytogenetic analysis and was included in the current
study. NGS revealed a deletion of one chromosome 16 between DNA
positions 3318842 and 4678939. This region contained, among other
genes, the CREB binding protein — CREBBP gene (chr16: 3710941–
3866165, 16p13.3). On this basis, a diagnosis of Rubinstein–Taybi
syndrome type 1 (RSTS1) was made for this patient.
A parent of this childwas also analysedwith NGS and oligoarray and
revealed a more downstream 3′ breakpoint of that deletion, not includ-
ing the CREBBP gene; hence the phenotype of this patientwas apparent-
ly normal (deletion on chr16: 4312849–4693138). A number of other
aberrations were revealed on 16p13.3 in both tests, showing the
power of the techniques to delineate more complex abnormalities.
The example presented shows the importance of deﬁning accurate
breakpoints of copynumber changes in a diagnostic service anddemon-
strates the ability of NGS to address this requirement.
3.7. Conclusion
Table 3 is included to summarise themain attributes of each technol-
ogy. Next generation sequencing is unique in its potential to offer con-
vergence of existing genetic technologies, with the possibility of a
single platform solution for genetic diagnosis of a range of abnormalities
from single gene mutations to aneuploidy. Modiﬁcation of the Illumina
operating protocols allows paired-end mapping, producing accurate po-
sitional data and possible detection of balanced rearrangements [16]. The
digital nature of the comparison means that once a normal control is se-
quenced, the dataset can be used for multiple patient samples.
Cost of the CNV-seqwill be competitivewith oligoarraywith the use
of the HiSeq and can also be adapted according to the level of resolution
required. The challenge, in the diagnostic setting, will be obtaining ac-
cess to a sequencer with availability at suitable times to ensure an ap-
propriate turnaround time.
The use of theNGS technology for the diagnosis of genetic disease has
been previously demonstrated [21]. In this study we have assessed theArrays (8 × 60k)
More targeted resolution in clinically interesting regions
Limited information outside of the target regions
‘Fixed’ resolution in backbone and targeted regions
‘Patient vs patient’ or ‘patient vs control’ run in the same experiment
In general, requires higher amount and good quality of DNA
Only unbalanced rearrangements can be detected
er Arrays do not offer such a potential
s access Extensive expertise in the use of arrays in cytogenetics
th the Relatively low cost of the platform has made it possible for arrays to be
used as a front-line test in many laboratories across the UK
Fig. 2. Number of reads per window ﬁtting into a gamma distribution model.
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setting and compared it against the UK gold standard of oligoarray
CGH.We show that clonal sequencing using the Illumina GAIIx platform
can perform high throughput copy number detection at a comparable
level to the oligoarray 8 × 60k platform. All purported pathogenic copy
number variants detected among a cohort of 39 childrenwith phenotyp-
ic abnormalities using the oligoarray method were successfully detected
by CNV-seq. In addition, a submicroscopic deletion at 2q23.1, which
remained undetected by the oligoarray platform, was revealed by NGS.
The digital nature of the NGS data means that the exact copy number
at each locus in the genome can be inferred. As the cost of sequencing
continues to fall, NGS technologies may offer a superior analysis pipeline
for the detection of chromosomal and genetic abnormalities on a single
platform.
4. Materials and methods
4.1. Sample selection
Thirty-nine patients with developmental delay and/or learning
difﬁculties referred to the Leeds Teaching Hospitals NHS Trust Cyto-
genetic Department for array CGH testing were selected. Genomic
DNA was extracted from whole blood using a salt-precipitation ex-
traction protocol [22] and stored at −20 °C.
4.2. Illumina Genome Analyzer library preparation
DNA concentration and purity were determined using the Quant-iT
PicoGreen ds DNA BR assay (Invitrogen, Paisley, UK) and the Agilent
Bioanalyzer Genechip (Agilent Ltd, UK). Two micrograms of genomic
DNA was used to prepare the DNA libraries for sequencing according
to standard protocols. DNA was sheared to approximately 150–200
base pairs using adaptive focused acoustics (Covaris S2, KBioscience,
Hertz, UK). Fragments were puriﬁed using MinElute columns (Qiagen,
Chatsworth, CA) and end repair was performed using the End-It DNA
End-Repair kit (EpiCentre, Madison, WI). Eight different adaptors
containing 6-nt barcodes were used to index the samples (LigaFast
Kit, Promega), using previously described methods [13]. Fragments
were size selected to 200 bp ± 25 bp from 2% TBE agarose gels
(QiaQuick Gel Extraction Kit, Qiagen). Following PCR ampliﬁcation,
the libraries were puriﬁed on a QiaQuick column and quality-checked
using an Agilent Bioanalyzer DNA 1000 LabChip, with quantiﬁcation
performed by a Quant-iT PicoGreen dsDNA assay. Equal amounts of
each tagged library were then pooled for cluster generation and se-
quencing using the standard Illumina single-read 76-cycle operating
protocol. 8 samples per lane of a ﬂow cell on the Illumina GaII (GaIIx)
were sequenced.
4.3. Array CGH processing
DNA was cleaned up using ethanol precipitation [23]. The
optimised BlueGnome protocol was used for processing CytoChip
8 × 60k oligoarrays including enzyme digestion, labelling, clean up,
hybridisation and washing [24]. Scanning was carried out according
to the manufacturer's protocol. Promega male and female controls
(ten pooled DNA samples) were used for this analysis.
4.4. Data analysis
Image analysis and base calling were performed using the Illumina
CASAVA pipeline. Subsequent analysis of copy number variation was
as previously reported [13]. Python scripts ﬁrst segregated the samples
according to their indexing tags. Readswere aligned to the reference se-
quence using the BWA alignment algorithm [25]. A custom designed
Python script was used to perform pair-wise comparisons of each test
and control sample; the genome was split into non-overlappingwindows of equal numbers of normal reads and the number of patient
reads within each windowwas counted. Prior to the statistical analysis,
the read counts were corrected for GC bias, achieved using the locally
weighted regression (LOESS) method [26]. An increased test:control
ratio indicates a gain whereas a decreased test:control ratio indicates
a loss.
The windows were deﬁned in such a way that the read count of the
patient sample in each window would be approximately 40 reads; this
window size offered a balance between resolution and noise. For the
purposes of the comparison, we used a bioinformatically constructed
control made of sequencing data from 20 normal, Caucasian individuals
of both sexes downloaded from the 1000 genomeproject [27]. Datawas
obtained from samples sequenced on Illumina platforms and trimmed
to the same read length andmerged.We restricted the analysis to auto-
somes since the reference sample was based on a mixture of males and
females.
Two methods of analysis are described below. The ﬁrst method
was a statistical-based method performed on the ﬁle obtained after
windows were generated for the sequencing and on the raw excel
ﬁle obtained from BlueGnome array processing.
The second, the proposed analysis protocol for the NGS data, more
closely resembles themethod of array analysis as it uses a segmentation
algorithm and log2 ratio thresholds to produce copy number calls.4.5. Analysis method #1 — direct comparison of NGS and oligoarray
technologies
The purpose of this was to compare the technology with the same
analysis method, before any low quality calls are removed.
A natural model for the read count in test sample i in windoww is:
yi;wePoisson ci;wλi=2
 
where λi is the average read count in sample i for a windowwith a copy
number of 2, and ci,w is (unknown) a copy number ofwindoww in sam-
ple i. However, since the processed read counts were not integers and
(more importantly) since they were overdispersed (which could, to
some extent, be expected due to statistical ﬂuctuations of the window
sizes), we decided to model the processed read counts as yi,
w ~ gamma (ci,wαi/2,βi), where the shape parameterαi and the rate pa-
rameter βi were estimated by ﬁtting the theoretical (0.25, 0.75)
quantiles to the corresponding empirical quantiles, utilising the fact
that the vast majority of the windows will have a copy number of 2.
The fractions Pi,c of the windows with copy number c were estimated
using the EM algorithm [28]. This model provided a very good ﬁt to
the data (Fig. 2).
Fig. 3. a. The region of imbalances detected on CNV-seq but not oligoarray. The top track shows the region identiﬁed to be deleted on the sequencing. This was detected in three
windows. The bottom track shows the microarray probes for the Agilent 8 × 60k platform. There are two probes just outside this region but no probes within the region. This region
on chromosome 2 is not a targeted area on the microarray so probe coverage is lower. b. The read numbers in each window across the region of the deleted 2q. Windows 31–33
(circled) have fewer reads in comparison to the other windows. Read numbers across a region can vary due to factors such as GC content and repetitive elements, for this reason
comparison to a control is essential.
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copy number aberrations using Bayes' formula:
p CNi;w ¼ c
 
¼
Pi;cdi;c yi;w
 
∑k¼1:aPi;kdi;k yi;w
 
where di,c is the ﬁtted density function for the read counts corre-
sponding to copy number c in sample i.
From these posterior probabilities, thresholds for CNV detection
can be constructed. In order to minimise the number of misclassiﬁed
genes, we decided to call a CNV when the posterior probability of a
CNV exceeds 0.5.
The separation of windows with normal and abnormal copy num-
bers becomes clearer when the calls are based on larger windows, e.g.
by fusing two or three adjacent windows. This is particularly relevant
for the gains, which are more difﬁcult to separate from the noise than
the deletions. For the purpose of comparison with the microarray
data, we generated CNV calls based on regions of three adjacent win-
dows and compared the NGS call to the microarray that mapped the
middle of the three windows. This allowed us to compare copy num-
ber calls from the two technologies at similar resolution.4.6. Analysis method #2 — comparison of the proposed method to
oligoarray analysed by proprietary software
The Leeds Cytogenetics Laboratory currently uses BlueGnome's pro-
prietary software, BlueFuse, for the analysis of oligoarray-CGH data. In
order to compare the data generated from the two platforms, we used
amethod that more closely resembled the commercial method of analy-
sis of oligoarrays, with segmentation applied. Thiswas then compared to
the results of the oligoarray when processed using the BlueFuse
software.
Following segmentation into windows across the genome, the pro-
posed NGS method of analysis involved normalisation of the read
counts, adjusting for differential read-depths between samples (full
code for this analysis is available in the Supplementary material). A
log2 ratio of normalised sample:control read count was then calculated
for eachwindow. Amean log2 ratio was generated for consecutive win-
dows and used to produce graphical representations of copy number
variation for each patient. Segments of equal copy number were called
using the Bioconductor DNAcopy package [29]. Log2 ratio thresholds
were set based on the midpoint between the baseline (0) and the
expected log2 of a heterozygous deletion (−1) and between the base-
line and the expected log2 of a heterozygous gain (0.58) resulting in
thresholds of−0.5 and +0.29. The minimum platform resolution was
181J.L. Hayes et al. / Genomics 102 (2013) 174–181deﬁned as being equal to the average genomic length of two read win-
dows as this was theminimum requirement for the generation of a dis-
tinct segment with this method.
Follow-up of imbalances detected on either platformwas performed
only if they contained disease genes and, in some cases, likely to be of
clinical signiﬁcance to the phenotype. It should also be noted that
some samples were not followed up due to lack of material.
4.7. Fluorescent in situ hybridisation (FISH) analysis
Metaphase spreads were prepared from peripheral blood lympho-
cytes using standard methodology. Chromosomes were visualised by
counterstaining with DAPI.
4.8. Quantitative PCR analysis
Q-PCR for follow-up of imbalances was carried out using primers
designed by and protocols supplied by Primer Design Ltd. Q-PCR
follow-up for the discordant abnormality identiﬁed in one patient was
performed by the Cytogenetics Laboratory at Addenbrookes Hospital
as part of a diagnostic test.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2013.04.006.
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